Filtered By:
Drug: Estradiol

This page shows you your search results in order of relevance. This is page number 10.

Order by Relevance | Date

Total 6429 results found since Jan 2013.

The NIEHS Superfund Research Program: 25 Years of Translational Research for Public Health
Conclusion: SRP must continue to address the legacy of hazardous waste in the United States, respond to new issues caused by rapid advances in technology, and train the next generation of leaders in environmental health science while recognizing that most of the world’s worst toxic hot spots are now located in low- and middle-income countries. Citation: Landrigan PJ, Wright RO, Cordero JF, Eaton DL, Goldstein BD, Hennig B, Maier RM, Ozonoff DM, Smith MT, Tukey RH. 2015. The NIEHS Superfund Research Program: 25 years of translational research for public health. Environ Health Perspect 123:909–918; http:/...
Source: EHP Research - September 30, 2015 Category: Environmental Health Authors: Sam Duvall Tags: Commentary October 2015 Source Type: research

A novel FOXL2 gene mutation and BMP15 variants in a woman with primary ovarian insufficiency and blepharophimosis–ptosis–epicanthus inversus syndrome
Conclusions: The novel, de novo FOXL2 gene mutation (p.K150Rfs*121) expands the spectrum of molecular defects identified in women with BPES. Coexisting gene variants in POI-related genes, such as BMP15, may act synergistically and explain the observed phenotypic variability in women with BPES (ie, BPES with or without POI). The concept of digenic inheritance suggested herein has been previously introduced for other nosologies such as hypogonadotrophic hypogonadism. Endocrine autoimmunity might also contribute to the POI phenotype.
Source: Menopause - October 30, 2015 Category: OBGYN Tags: Case Report Source Type: research

Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction.
CONCLUSIONS: In women identified as poor responders undergoing ART, pre-treatment with DHEA or testosterone may be associated with improved live birth rates. The overall quality of the evidence is moderate. There is insufficient evidence to draw any conclusions about the safety of either androgen. Definitive conclusions regarding the clinical role of either androgen awaits evidence from further well-designed studies. PMID: 26608695 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - November 26, 2015 Category: Journals (General) Authors: Nagels HE, Rishworth JR, Siristatidis CS, Kroon B Tags: Cochrane Database Syst Rev Source Type: research

Efficacy and Safety Profile of Diclofenac/Cyclodextrin and Progesterone/Cyclodextrin Formulations: A Review of the Literature Data
Conclusions As shown by the results of clinical studies presented in this review, the newly approved medicines containing cyclodextrins have been found to be as effective and as well-tolerated as other medicinal products that do not contain cyclodextrins. Moreover, the newly approved lower dose of diclofenac associated with cyclodextrins is consistent with the European Medicines Agency recommendations reported in the revision of the Assessment Report for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Cardiovascular Risk. Finally, the use of cyclodextrins led to significant increases in solubility and bioavail...
Source: Drugs in R&D - March 3, 2016 Category: Drugs & Pharmacology Source Type: research

Rationale for eliminating the hormone-free interval in modern oral contraceptives
Conclusions Extended regimens with modified HFIs might provide greater ovarian suppression with the potential for increased contraceptive effectiveness. Additional research is needed to evaluate whether COC regimens that include 10μg ethinyl estradiol instead of an HFI might improve tolerability.
Source: International Journal of Gynecology and Obstetrics - March 21, 2016 Category: OBGYN Source Type: research

Effects of ospemifene on bone parameters including clinical biomarkers in postmenopausal women
Conclusions: Ospemifene 60 mg/d may have a protective effect on the bone health of women being treated for dyspareunia. The initial clinical data for ospemifene follows a trend similar to raloxifene and bazedoxifene, suggesting that ospemifene may have bone-protective effects in postmenopausal women. However, additional rigorous clinical trials are necessary to confirm any positive effects ospemifene may have on vertebral fractures and bone mineral density in healthy and osteoporotic women.
Source: Menopause - May 21, 2016 Category: OBGYN Tags: Original Articles Source Type: research

Anti-androgenic, anti-oestrogenic and antioxidant activities of aqueous extract of Laportea ovalifolia on adults rats.
Cancer is one of the most life-threatening diseases in which deregulating proliferation of abnormal cells invades and disrupts surrounding tissues. It constitutes seriouspublic health problems in both developed and developing countries.To evaluate the anti-androgenic, anti-estrogenic and antioxidant activities of Laportea ovalifolia (L. ovalifolia) in order to contribute to the search and the valorization of medicinal plants which could reduce mortality related to prostate cancer.The evaluation of the anti-androgenic activity were carried out on castrated male rats receiving simultaneous daily administration of testosteron...
Source: International Journal of Phytomedicine - June 18, 2016 Category: Science Authors: Sylvain Nguedia Njina Source Type: research

Bioidentical hormones for women with vasomotor symptoms.
CONCLUSIONS: There was low to moderate quality evidence that BHT in various forms and doses is more effective than placebo for treating moderate to severe menopausal hot flushes. There was low to moderate quality evidence of higher rates of adverse effects such as headache, vaginal bleeding, breast tenderness and skin reactions in the BHT group. There was some evidence to suggest that higher doses of BHT are associated with greater effectiveness but also with higher risk of adverse effects. Although all the included studies used unopposed estrogen, it is recommended best practice to use progestogen therapy in women with a ...
Source: Cochrane Database of Systematic Reviews - July 31, 2016 Category: Journals (General) Authors: Gaudard AM, Silva de Souza S, Puga ME, Marjoribanks J, da Silva EM, Torloni MR Tags: Cochrane Database Syst Rev Source Type: research

Hormonal contraceptives for contraception in overweight or obese women.
CONCLUSIONS: The evidence generally did not indicate an association between higher BMI or weight and effectiveness of hormonal contraceptives. However, we found few studies for most contraceptive methods. Studies using BMI, rather than weight alone, can provide information about whether body composition is related to contraceptive effectiveness. The contraceptive methods examined here are among the most effective when used according to the recommended regimen.We considered the overall quality of evidence to be low for the objectives of this review. More recent reports provided evidence of varying quality, while the quality...
Source: Cochrane Database of Systematic Reviews - August 17, 2016 Category: Journals (General) Authors: Lopez LM, Bernholc A, Chen M, Grey TW, Otterness C, Westhoff C, Edelman A, Helmerhorst FM Tags: Cochrane Database Syst Rev Source Type: research

Hormonal contraceptives: pharmacology tailored to women's health
CONCLUSION Progress in the provision of new oral contraceptives has improved the risk/benefit ratio, by increasing benefits and reducing risks. The present challenge is to tailor contraceptives to individual needs in terms of efficacy and protection of reproductive health.
Source: Human Reproduction Update - August 25, 2016 Category: OBGYN Authors: De Leo, V., Musacchio, M. C., Cappelli, V., Piomboni, P., Morgante, G. Tags: Review Source Type: research

Environmental impact of estrogens on human, animal and plant life: A critical review.
CONCLUSIONS: There is published evidence to establish a causal relationship between estrogens in the environment and breast cancer. However, there are serious gaps in our knowledge about estrogen levels in the environment and a call is required for a world wide effort to provide more data on many more samples sites. Of the data available, the synthetic estrogen, ethinyl estradiol, is more persistent in the environment than natural estrogens and may be a greater cause for environmental concern. Finally, we believe that there is an urgent requirement for inter-disciplinary studies of estrogens in order to better understand t...
Source: Environment International - December 27, 2016 Category: Environmental Health Authors: Adeel M, Song X, Wang Y, Francis D, Yang Y Tags: Environ Int Source Type: research

Effect of metformin on clinical, metabolic and endocrine outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trial.
CONCLUSION: Metformin showed significant improvement in clinical outcomes but not in metabolic and endocrine outcomes in PCOS women; however, heterogeneity between studies was found to be moderate to high. PMID: 28058854 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - January 11, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research

Hormonal Regulation of Nitric Oxide (NO) in Cardio-Metabolic Diseases.
CONCLUSION: Understanding the regulation of NO production by different hormones such as E2, and IGF-1 may provide novel and useful knowledge regarding how endothelial dysfunction (ED) is linked with cardio-metabolic alterations and diseases. PMID: 28120715 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - January 23, 2017 Category: Drugs & Pharmacology Authors: Sudar-Milovanovic E, Zafirovic S, Jovanovic A, Trebaljevac J, Obradovic M, Cenic-Milosevic D, Isenovic ER Tags: Curr Pharm Des Source Type: research

Regulation of Na+/K+-ATPase by estradiol and IGF-1 in cardio-metabolic diseases.
CONCLUSION: Understanding the molecular mechanisms of estradiol and IGF-1 action on Na+/K+-ATPase in humans, may help resolving outstanding issues and developing new strategies for the protection and treatment of cardiovascular diseases. PMID: 28164755 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - February 2, 2017 Category: Drugs & Pharmacology Authors: Obradovic M, Stanimirovic J, Panic A, Bogdanovic N, Sudar-Milovanovic E, Cenic-Milosevic D, Isenovic ER Tags: Curr Pharm Des Source Type: research

Research development of a new GnRH antagonist (Elagolix) for the treatment of endometriosis: a review of the literature
ConclusionGnRH antagonists may have the advantage of oral administration and lower incidence of adverse events. Currently, only Phase II studies have been published demonstrating promising results in terms of efficacy, safety, and tolerability. From the results of the phase III studies, elagolix may become a valuable addition to the armamentarium of pharmacological agents to treat endometriosis-related pain.
Source: Archives of Gynecology and Obstetrics - March 2, 2017 Category: OBGYN Source Type: research